Sage Journals: Discover world-class research

Abstract

Introduction

Ever since the late 1970s, occupational exposure associated with the handling of antineoplastic drugs (ADs) in the healthcare environment has been highlighted and demonstrated. Contamination was detected in both operating rooms (OR) and compounding units (CU), where healthcare workers handle and are exposed to ADs in different ways. In the OR, the risk of exposure is higher and the staff receives less training in handling ADs than in the CU. This study aimed to assess and compare knowledge and practices about the safe handling of ADs by caregivers working in these two locations, namely the CU and OR.

Methods

Two questionnaires (one each for the OR and CU) were created by two investigator pharmacists and were completed during a personal interview of 20 min. The questions were related to the following topics: training, knowledge about occupational exposure and questions related to protective practices. A scoring system was implemented to assess the knowledge and practices of each participant.

Results

In total, 38 caregivers working in the OR and 39 in the CU were included in our study. Significantly more CU staff had specific initial training (p < 0.001) and ongoing training (p < 0.001) in handling ADs. Concerning the knowledge score, OR caregivers had a significantly lower median score for contamination routes (p < 0.001), contamination surfaces (p < 0.001), existing procedures (p < 0.001) and total knowledge (p < 0.001) than CU caregivers. Concerning protective handling practices of ADs, the two locations had nonsignificantly different median scores (p = 0.892).

Conclusion

This study suggests that there is still room for improvement in terms of knowledge and protection practices when handling ADs. An appropriate and tailored training program should be developed and provided to all caregivers who handle or come in contact with ADs.

Clinical trial registration

Study CONTACT, ref. 19-504.

Keywords

Antineoplastic drugs occupational exposure healthcare workers knowledge practices training operating rooms compounding units

Get full access to this article

View all access options for this article.

References

Falck

Gröhn

Sorsa

, et al. Mutagenicity in urine of nurses handling cytostatic drugs. Lancet Lond Engl 1979; 1: 1250–1251.

McDiarmid

Oliver

Roth

, et al. Chromosome 5 and 7 abnormalities in oncology personnel handling anticancer drugs. J Occup Environ Med Am Coll Occup Environ Med 2010; 52: 1028–1034.

Connor

Lawson

Polovich

, et al. Reproductive health risks associated with occupational exposures to antineoplastic drugs in health care settings: a review of the evidence. J Occup Environ Med Am Coll Occup Environ Med 2014; 56: 901–910.

Roussel

Witt

Shaw

, et al. Meta-analysis of chromosomal aberrations as a biomarker of exposure in healthcare workers occupationally exposed to antineoplastic drugs. Mutat Res Rev Mutat Res 2019; 781: 207–217.

National Institute for Occupational Safety and Health (NIOSH). Preventing occupational exposure to antineoplastic and other hazardous drugs in health care settings, https://www.cdc.gov/niosh/docs/2004-165/pdfs/2004-165.pdf?id=10.26616/NIOSHPUB2004165 (2004, accessed 30 March 2022).

Occupational Safety and Health Administration. Safety and Health Program Management Guidelines, https://www.osha.gov/sites/default/files/SHPM_guidelines.pdf (2015, accessed 30 March 2022).

Association pour la Santé et la Sécurité du Travail, Secteur Affaires Sociales. Guide de prévention - Manipulation sécuritaire des médicaments dangereux, http://asstsas.qc.ca/sites/default/files/publications/documents/Guides_Broch_Depl/GP65-medicaments_dangereux06-2021.pdf (2021, accessed 30 March 2022).

International Society of Oncology Pharmacy Practicioners Standards Committee. ISOPP standards of practice. Safe handling of cytotoxics. J Oncol Pharm Pract Off Publ Int Soc Oncol Pharm Pract 2007; 13 Suppl: 1–81.

Power

Coyne

. ASHP Guidelines on handling hazardous drugs. Am J Health-Syst Pharm AJHP Off J Am Soc Health-Syst Pharm 2018; 75: 1996–2031.

10.

Eisenberg

. USP <800> and strategies to promote hazardous drug safety. J Infus Nurs Off Publ Infus Nurses Soc 2018; 41: 12–23.

11.

Delafoy

Roussy

Hudon

A-F

, et al. Canadian monitoring program of the surface contamination with 11 antineoplastic drugs in 122 centers. J Oncol Pharm Pract Off Publ Int Soc Oncol Pharm Pract 2022. 10781552211072876

12.

Martín Lancharro

De Castro-Acuña Iglesias

González-Barcala

F-J

, et al. Evidence of exposure to cytostatic drugs in healthcare staff: a review of recent literature. Farm Hosp Organo Of Expresion Cient Soc Espanola Farm Hosp 2016; 40: 604–621.

13.

Hon

C-Y

Teschke

Demers

, et al. Antineoplastic drug contamination on the hands of employees working throughout the hospital medication system. Ann Occup Hyg 2014; 58: 761–770.

14.

Delafoy

Chabut

Tanguay

, et al. Efficacy of two intensive decontamination protocols and their effects after 30 days on environmental contamination by cyclophosphamide. Pharm Technol Hosp Pharm 2021; 6: 20210006.

15.

Simon

Vasseur

Pinturaud

. Effectiveness of a closed-system transfer device in reducing surface contamination in a new antineoplastic drug-compounding unit: a prospective, controlled, parallel study. PLoS One 2016; 11: e0159052.

16.

Werumeus Buning

Geersing

Crul

. The assessment of environmental and external cross-contamination in preparing ready-to-administer cytotoxic drugs: a comparison between a robotic system and conventional manual production. Int J Pharm Pract 2020; 28: 66–74.

17.

Crauste-Manciet

Sessink

PJM

Ferrari

, et al. Environmental contamination with cytotoxic drugs in healthcare using positive air pressure isolators. Ann Occup Hyg 2005; 49: 619–628.

18.

Fleury-Souverain

Nussbaumer

Mattiuzzo

, et al. Determination of the external contamination and cross-contamination by cytotoxic drugs on the surfaces of vials available on the Swiss market. J Oncol Pharm Pract Off Publ Int Soc Oncol Pharm Pract 2014; 20: 100–111.

19.

Hilliquin

Tanguay

Bussières

J-F

. External contamination of commercial containers by antineoplastic agents: a literature review. Eur J Hosp Pharm Sci Pract 2020; 27: 313–314.

20.

Cotteret

Secretan

P-H

Gilles-Afchain

, et al. External contamination of antineoplastic drug vials: an occupational risk to consider. Eur J Hosp Pharm Sci Pract 2022; 29: 284–286.

21.

Mekoba

Turingan

Roberts

, et al. A pharmacy-led United States Pharmacopeia (USP) chapter 800 compliance collaborative at an academic medical center. Am J Health-Syst Pharm AJHP Off J Am Soc Health-Syst Pharm 2018; 75: 627–632.

22.

Sugarbaker

. Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis. Semin Surg Oncol 1998; 14: 254–261.

23.

Glehen

Kwiatkowski

Sugarbaker

, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 2004; 22: 3284–3292.

24.

Rodier

Saint-Lorant

Guilloit

, et al.

Is hyperthermic intraperitoneal chemotherapy (HIPEC) safe for healthcare workers?

Surg Oncol 2017; 26: 242–251.

25.

Solass

Giger-Pabst

Zieren

, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC): occupational health and safety aspects. Ann Surg Oncol 2013; 20: 3504–3511.

26.

Ferron

Simon

Guyon

, et al. Professional risks when carrying out cytoreductive surgery for peritoneal malignancy with hyperthermic intraperitoneal chemotherapy (HIPEC): a French multicentric survey. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol 2015; 41: 1361–1367.

27.

Benoist

Breuil

Le Neindre

, et al.

Does equipment change impact blood contamination with irinotecan and its two major metabolites in a centralized cytotoxic pharmacy unit?

J Oncol Pharm Pract Off Publ Int Soc Oncol Pharm Pract 2020; 26: 1823–1828.

28.

Béchet

Benoist

Beau

, et al. Blood contamination of the pharmaceutical staff by irinotecan and its two major metabolites inside and outside a compounding unit. J Oncol Pharm Pract Off Publ Int Soc Oncol Pharm Pract 2022; 28: 777–784.

29.

Saint-Lorant

Rodier

Guilloit

J-M

, et al.

Is the blood of a surgeon performing HIPEC contaminated by irinotecan, its major metabolites and platinum compounds?

Pleura Peritoneum 2021; 6: 49–55.

30.

Boiano

Steege

Sweeney

. Adherence to safe handling guidelines by health care workers who administer antineoplastic drugs. J Occup Environ Hyg 2014; 11: 728–740.

31.

Constantinidis

Vagka

Dallidou

, et al. Occupational health and safety of personnel handling chemotherapeutic agents in Greek hospitals. Eur J Cancer Care (Engl) 2011; 20: 123–131.

32.

Hon

C-Y

Teschke

Shen

. Health care workers’ knowledge, perceptions, and behaviors regarding antineoplastic drugs: survey from British Columbia, Canada. J Occup Environ Hyg 2015; 12: 669–677.

33.

Benoist

Busson

Faveyrial

, et al. Perception, knowledge, and handling practice regarding the risk of exposure to antineoplastic drugs in oncology day hospitalization units and compounding unit staff. J Oncol Pharm Pract Off Publ Int Soc Oncol Pharm Pract 2022: 10781552221103804.

34.

Silver

Steege

Boiano

. Predictors of adherence to safe handling practices for antineoplastic drugs: a survey of hospital nurses. J Occup Environ Hyg 2015; 0: 1–29.

35.

Polovich

. USP general chapter<800>: considerations for oncology nursing practice. Semin Oncol Nurs 2020; 36: 151022.

36.

Ametsbichler

Böhlandt

Nowak

, et al.

Occupational exposure to cisplatin/oxaliplatin during Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC)?

Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol 2018; 44: 1793–1799.

37.

Larroque

Arnaudguilhem

Bouyssiere

, et al. Evaluation of the environmental contamination and exposure risk in medical/non-medical staff after oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy. Toxicol Appl Pharmacol 2021; 429: 115694.

38.

Kyriazanos

Kalles

Stefanopoulos

, et al. Operating personnel safety during the administration of Hyperthermic Intraperitoneal Chemotherapy (HIPEC). Surg Oncol 2016; 25: 308–314.

39.

Zhengzheng Xie

Yan

, et al. Evaluation of exposure risk for healthcare personnel performing the open technique HIPEC procedure using cisplatin. Gynecol Oncol 2021; 161: 261–263.

40.

Böhlandt

Groeneveld

Fischer

, et al. Cleaning efficiencies of three cleaning agents on four different surfaces after contamination by gemcitabine and 5-fluorouracile. J Occup Environ Hyg 2015; 12: 384–392.

41.

Queruau Lamerie

Nussbaumer

Décaudin

, et al. Evaluation of decontamination efficacy of cleaning solutions on stainless steel and glass surfaces contaminated by 10 antineoplastic agents. Ann Occup Hyg 2013; 57: 456–469.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.03 MB

0.00 MB

0.03 MB

Knowledge and practices about safe handling regarding the risk of exposure to antineoplastic drugs for caregivers in compounding units and in operating rooms performing HIPEC/PIPAC

Abstract

Introduction

Methods

Results

Conclusion

Keywords

Get full access to this article

References

Supplementary Material